Britain and America have agreed to a landmark bilateral deal that will preserve zero import taxes on British pharmaceutical shipments entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost expenditure on drugs through the NHS. This move ensures that tariffs on these crucial exports will remain at nothing for a period of three years.
This deal follows previous statements to dramatically increase duties on patented drug imports, with figures discussed as high as one hundred percent.
"This deal between the Britain strengthens the global environment for innovative medicines and establishes long-overdue balance to transatlantic drug exports," an announcement declared.
Trade Importance
Drugs are one of the UK's largest exports to the US, which is by far the primary market for leading companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months leading up to the third quarter, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This value made up 17.4% of all goods exports in that timeframe.
"This agreement secures work, boosts investment and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary remarked.
Detailed NHS Changes
The pact includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to double overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must return to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments were more than 20%.
Broader Context
The pact takes place against a long-running row between the pharmaceutical industry and the ministers over medicine costs and approval rates.
The disagreement were exacerbated by claims that American patients were paying a premium for the equivalent treatments than patients in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a percentage of its resources over the last ten years.
